Programmable transdermal clonidine delivery through voltage-gated carbon nanotube membranes

Journal of Pharmaceutical Sciences

Volumn 103, Issue 6, 2014, Pages 1829-1838

  Strasinger, Caroline ^a   Paudel, Kalpana S ^a,b   Wu, Ji ^c,f   Hammell, Dana ^a,d   Pinninti, Raghotham R ^a   Hinds, Bruce J ^c   Stinchcomb, Audra ^a,d,e  

^a University of Kentucky   (United States)

^b South College School of Pharmacy   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d AllTranz Inc   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^f GEORGIA SOUTHERN UNIVERSITY   (United States)

Author keywords

active transport; carbon nanotube membrane; clonidine; diffusion; drug addiction; membrane transport; nanotechnology; programmable drug delivery; skin permeation; transdermal delivery

Indexed keywords

CARBON NANOTUBE; CLONIDINE; DOUBLE WALLED NANOTUBE; MULTI WALLED NANOTUBE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;

ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DIFFUSION; DRUG ELIMINATION; DRUG PENETRATION; DRUG SOLUTION; DRUG TRANSPORT; ELECTRIC POTENTIAL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; OPIATE SUBSTITUTION TREATMENT; SKIN PENETRATION; SKIN PERMEABILITY; SKIN SURFACE; STEADY STATE; TRANSDERMAL PATCH; WITHDRAWAL SYNDROME; FEASIBILITY STUDY; INTRADERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; CLONIDINE; FEASIBILITY STUDIES; HUMANS; NANOTUBES, CARBON;

EID: 84901207687     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23940     Document Type: Article

References (28)

1. Chen SQ, Zhai HF, Cui YY, Shi J, Le Foll B, Lu L,. 2007. Clonidine attenuates morphine withdrawal and subsequent drug sensitization in rhesus monkeys. Acta Pharmacol Sin 28: 473-483.
2. National Institute on Drug Addiction. 2006. Research report series-Heroin abuse and addiction.
3. Oreskovich MR, Saxon AJ, Ellis ML, Malte CA, Reoux JP, Knox PC., 2005. A double-blind, double-dummy, randomized, prospective pilot study of the partial Mu opiate agonist, buprenorphine, for acute detoxification from heroin. Drug Alcohol Depend 77: 71-79.
4. Wills S,. 2005. Drugs of abuse. 2nd ed. Chicago, Illinois: Pharmaceutical Press.
5. Gowing L, Farrell M, Ali R, White JM,. 2009. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 15: CD002024.
6. Raith K, Hochhaus G,. 2004. Drugs used in the treatment of opioid tolerance and physical dependence: A review. Int J Clin Pharmacol Ther 42: 191-203.
7. Sobey PW, Parran TV Jr, Grey SF, Adelman CL, Yu J,. 2003. The use of tramadol for acute heroin withdrawal: A comparison to clonidine. J Addict Dis 22: 13-25.
8. Strobbe S, Brower KJ, Galen LW,. 2003. Predicting completion of outpatient opioid detoxification with clonidine. Am J Addict 12: 260-269.
9. Berner B, John VA,. 1994. Pharmacokinetic characterisation of transdermal delivery systems. Clin Pharmacokinet 26: 121-134.
10. Claxton AJ, Cramer J, Pierce C,. 2001. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23: 1296-1310.
11. Lanier RK, Umbricht A, Harrison JA, Nuwayser ES, Bigelow GE,. 2008. Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: An open-label evaluation. Psychopharmacology 198: 149-158.
12. Lochner S, Heinrich-Gräfe U, Kirch W,. 2010. Withdrawal in a patient with an implantable drug delivery system in spite of continuation of opiate therapy. Internist 51: 667-669.
13. Segal IS, Jarvis DJ, Duncan SR, White PF, Maze M,. 1991. Clinical efficacy of oral-transdermal clonidine combinations during the perioperative period. Anesthesiology 74: 220-225.
14. Umbricht A, Hoover DR, Tucker MJ, Leslie JM, Chaisson RE, Preston KL,. 2003. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. Drug Alcohol Depend 69: 263-272.
15. Drugs@FDA. Accessed July 30, 2010, at: http://www.accessdata.fda.gov/ Scripts/cder/DrugsatFDA/.
16. Drugs.com. Accessed July 30, 2010, at: www.drugs.com/pro/clonidine-patch. html.
17. Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL,. 2010. Challenges and opportunities in dermal/transdermal delivery. Ther Deliv 1: 109-131.
18. Sica DA, Grubbs R,. 2005. Transdermal clonidine: Therapeutic considerations. J Clin Hypertens 7: 558-562.
19. Hinds BJ, Chopra N, Rantell T, Andrews R, Gavalas V, Bachas LG,. 2004. Aligned multiwalled carbon nanotube membranes. Science 303: 62-65.
20. Majumder M, Stinchcomb A, Hinds BJ,. 2010. Towards mimicking natural protein channels with aligned carbon nanotube membranes for active drug delivery. Life Sci 86: 563-568.
21. Majumder M, Chopra N, Andrews R, Hinds BJ,. 2005. Nanoscale hydrodynamics: Enhanced flow in carbon nanotubes. Nature 438: 44-44.
22. Majumder M, Keis K, Zhan X, Meadows C, Cole J, Hinds BJ,. 2008. Enhanced electrostatic modulation of ionic diffusion through carbon nanotube membranes by diazonium grafting chemistry. J Membr Sci 316: 89-96.
23. Majumder M, Zhan X, Andrews R, Hinds BJ,. 2007. Voltage gated carbon nanotube membranes. Langmuir 23: 8624-8631.
24. Wu J, Paudel KS, Strasinger C, Hammell D, Stinchcomb AL, Hinds BJ,. 2010. Programmable transdermal drug delivery of nicotine using carbon nanotube membranes. Proc Natl Acad Sci USA 107: 11698-11702.
25. Ashburn MA, Streisand J, Zhang J, Love G, Rowin M, Niu S, Kievit JK, Kroep JR, Mertens MJ,. 1995. The iontophoresis of fentanyl citrate in humans. Anesthesiology 82: 1146-1153.
26. D'Amour M, Bélanger D,. 2003. Stability of substituted phenyl groups electrochemically grafted at carbon electrode surface. J Phys Chem B 107: 4811-4817.
27. DRUGDEX. 2008. Clonidine. In DRUGDEX system. Thomson Reuters (Healthcare) Inc.
28. Wu J, Gerstandt K, Majumder M, Zhan X, Hinds BJ,. 2011. Highly efficient electroosmotic flow through functionalized carbon nanotube membranes. Nanoscale 3: 3321-3328.